StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note released on Monday. The firm issued a hold rating on the stock.
NovaBay Pharmaceuticals Trading Up 4.9 %
Shares of NYSE NBY opened at $0.73 on Monday. The stock has a market cap of $789,860.00, a P/E ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $15.75. The stock has a 50 day moving average of $0.57 and a two-hundred day moving average of $2.24.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 91.86%. The business had revenue of $2.40 million for the quarter. As a group, research analysts predict that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current year.
Institutional Inflows and Outflows
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Featured Articles
- Five stocks we like better than NovaBay Pharmaceuticals
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- When Is the Best Time to Invest in Mutual Funds?
- Where Do I Find 52-Week Highs and Lows?
- Is NVIDIA Stock in a Correction or Consolidation?
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.